肺癌免疫治疗的研究进展  

Research progress of immunotherapy for lung cancer

作　　者：张旭 曹婉昕 李晓雪 杨红 李婉 迟湘胤 杜冠华 王金华 ZHANG Xu;CAO Wanxin;LI Xiaoxue;YANG Hong;LI Wan;CHI Xiangyin;DU Guanhua;WANG Jinhua(Beijing Key Laboratory of Drug Target Research and New Drug Screening,Institute of Materia Medica,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing 100050,China)

机构地区：[1]中国医学科学院、北京协和医学院药物研究所,药物靶点研究与新药筛选北京市重点实验室,北京100050

出　　处：《现代肿瘤医学》2025年第4期525-547,共23页Journal of Modern Oncology

基　　金：中国医学科学院创新工程基金(编号:2021-I2M-1-029,2023-I2M-2-006);国家外国专家项目(编号:G2023194008L)。

摘　　要：肺癌是全球范围内最常见的恶性肿瘤之一,发病率和死亡率均位列各类癌症之首,其中以非小细胞肺癌最为常见。目前肺癌的药物治疗主要为化学疗法、靶向疗法及免疫疗法。化学疗法获益有限且副作用明显,近年来肺癌的免疫治疗取得突破,前景广阔,效果良好。该文综述肺癌免疫治疗的最新进展,包括免疫检查点抑制剂疗法、CAR-T疗法、CAR-NK疗法、溶瘤病毒疗法和肺癌疫苗,以期为肺癌患者的临床免疫治疗和肺癌的免疫治疗基础研究提供思路和参考。Lung cancer is one of the most malignant cancers in the world,with the highest incidence and mortality rates among all types of cancer.Non-small cell lung cancer is the common subtype of lung cancer.Current drug treatments for lung cancer mainly includs chemotherapy,targeted therapy and immunotherapy.Chemotherapy have limited benefit and significant side effects.In recent years,immunotherapy for lung cancer has made great progress,with broad prospects and good results.This article reviews the latest progress in immunotherapy of lung cancer,including immune checkpoint inhibitor therapy,CAR-T therapy,CAR-NK therapy,oncolytic virus therapy and lung cancer vaccines,in order to provide insights for clinical and basic research on lung cancer immunotherapy.

关 键 词：免疫治疗 免疫检查点 CAR-T CAR-NK 溶瘤病毒 疫苗 

分 类 号：R734.2[医药卫生—肿瘤]